About BioMarin Pharmaceutical
BioMarin Pharmaceutical is a company based in San Rafael (United States) founded in 1997.. BioMarin Pharmaceutical has raised $37.5 million across 7 funding rounds from investors including Pfizer, Temasek and BB Biotech Ventures. The company has 3,040 employees as of December 31, 2024. BioMarin Pharmaceutical has completed 7 acquisitions, including Amicus Therapeutics, Inozyme Pharma and Kuvan. BioMarin Pharmaceutical operates in a competitive market with competitors including Ultragenyx, Alnylam, Gemini Therapeutics, Mirum Pharmaceuticals and Immusoft, among others.
- Headquarter San Rafael, United States
- Employees 3040 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Biomarin Pharmaceutical Inc.
-
Annual Revenue
$2.84 B17.35as on Dec 31, 2024
-
Net Profit
$426.86 M154.62as on Dec 31, 2024
-
EBITDA
$626.23 M109.56as on Dec 31, 2024
-
Total Equity Funding
$37.5 M (USD)
in 7 rounds
-
Latest Funding Round
$500 M (USD), Post-IPO
May 11, 2020
-
Investors
Pfizer
& 3 more
-
Employee Count
3040
as on Dec 31, 2024
-
Investments & Acquisitions
Amicus Therapeutics
& 6 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of BioMarin Pharmaceutical
BioMarin Pharmaceutical is a publicly listed company on the NASDAQ with ticker symbol BMRN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Unlock access to complete
Software Development Team
179 people
Leadership Team
154 people
Senior Team
62 people
Operations Team
52 people
Product Management Team
39 people
Legal and Compliance
33 people
Finance and Accounting
25 people
Sales and Marketing
20 people
Unlock access to complete
Funding Insights of BioMarin Pharmaceutical
BioMarin Pharmaceutical has successfully raised a total of $37.5M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $500 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Post-IPO — $500.0M
-
First Round
First Round
(28 Feb 1997)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2020 | Amount | Post-IPO - BioMarin Pharmaceutical | Valuation |
investors |
|
| Nov, 2018 | Amount | Debt – Conventional - BioMarin Pharmaceutical | Valuation |
investors |
|
| Jun, 2018 | Amount | Post-IPO - BioMarin Pharmaceutical | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in BioMarin Pharmaceutical
BioMarin Pharmaceutical has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, Temasek and BB Biotech Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
An investment platform is provided for diverse sectors and geographies.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
ROMA99 is recognized as a trusted online gaming platform.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by BioMarin Pharmaceutical
BioMarin Pharmaceutical has strategically engaged in corporate development activities, having acquired 7 companies. Notable acquisitions include Amicus Therapeutics, Inozyme Pharma and Kuvan. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of treatments for rare and debilitating metabolic diseases
|
2016 | ||||
|
Drug discovery company developing therapeutics for cancer and infectious diseases treatment.
|
2006 | ||||
|
Small molecule therapeutics targeting glycan biosynthesis are developed.
|
2004 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - BioMarin Pharmaceutical
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Biomarin Pharmaceutical Comparisons
Competitors of BioMarin Pharmaceutical
BioMarin Pharmaceutical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ultragenyx, Alnylam, Gemini Therapeutics, Mirum Pharmaceuticals and Immusoft, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
Developer of precision therapeutics for dry AMD and rare genetic diseases
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| domain | founded_year | HQ Location |
B cells are programmed as biofactories for therapeutic protein delivery.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Biomarin Pharmaceutical
Frequently Asked Questions about BioMarin Pharmaceutical
When was BioMarin Pharmaceutical founded?
BioMarin Pharmaceutical was founded in 1997.
Where is BioMarin Pharmaceutical located?
BioMarin Pharmaceutical is headquartered in San Rafael, United States. It is registered at San Rafael, California, United States.
Who is the current CEO of BioMarin Pharmaceutical?
Jean Jacques Bienaime is the current CEO of BioMarin Pharmaceutical.
Is BioMarin Pharmaceutical a funded company?
BioMarin Pharmaceutical is a funded company, having raised a total of $37.5M across 7 funding rounds to date. The company's 1st funding round was a Post-IPO of $20M, raised on Feb 28, 1997.
How many employees does BioMarin Pharmaceutical have?
As of Dec 31, 2024, the latest employee count at BioMarin Pharmaceutical is 3,040.
What is the annual revenue of BioMarin Pharmaceutical?
Annual revenue of BioMarin Pharmaceutical is $2.84B as on Dec 31, 2024.
What does BioMarin Pharmaceutical do?
BioMarin Pharmaceutical was founded in 1997 and is headquartered in San Rafael, United States. Therapeutics are developed by the company for rare genetic diseases within the biopharmaceutical sector. Multiple products have been created for conditions including mucopolysaccharidosis syndrome and phenylketonuria. Additional therapies are being advanced for disorders such as Duchenne muscular dystrophy, hemophilia A, and Pompe disease. Operations focus on research and product development for these specialized treatments.
Who are the top competitors of BioMarin Pharmaceutical?
BioMarin Pharmaceutical's top competitors include Alnylam, Pharvaris and Ultragenyx.
Is BioMarin Pharmaceutical publicly traded?
Yes, BioMarin Pharmaceutical is publicly traded on NASDAQ under the ticker symbol BMRN.
How many acquisitions has BioMarin Pharmaceutical made?
BioMarin Pharmaceutical has made 7 acquisitions, including Amicus Therapeutics, Inozyme Pharma, and Kuvan.
Who are BioMarin Pharmaceutical's investors?
What is BioMarin Pharmaceutical's ticker symbol?
The ticker symbol of BioMarin Pharmaceutical is BMRN on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.